as of 03-06-2026 3:43pm EST
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEWPORT BEACH |
| Market Cap: | 304.0M | IPO Year: | 2018 |
| Target Price: | $15.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | 1.23 |
| 52 Week Low/High: | $4.09 - $13.66 | Next Earning Date: | 05-21-2026 |
| Revenue: | $297,176,000 | Revenue Growth: | 11.61% |
| Revenue Growth (this year): | 14.41% | Revenue Growth (next year): | 16.96% |
| P/E Ratio: | -7.10 | Index: | N/A |
| Free Cash Flow: | -45706000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See Remarks
Avg Cost/Share
$7.15
Shares
10,539
Total Value
$75,361.23
Owned After
354,388
SEC Form 4
See Remarks
Avg Cost/Share
$7.15
Shares
2,261
Total Value
$16,167.73
Owned After
356,821
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | EOLS | See Remarks | Dec 22, 2025 | Sell | $7.15 | 10,539 | $75,361.23 | 354,388 | |
| Avelar Rui | EOLS | See Remarks | Dec 22, 2025 | Sell | $7.15 | 2,261 | $16,167.73 | 356,821 |
SEC 8-K filings with transcript text
Mar 3, 2026 · 100% conf.
1D
-7.03%
$5.27
5D
-10.69%
$5.06
20D
-8.67%
$5.17
eols-202603030001570562false00015705622026-03-032026-03-03
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 3, 2026
(Exact name of registrant as specified in its charter)
Delaware 001-38381 46-1385614
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
520 Newport Center Drive, Suite 1200 Newport Beach, California 92660 (Address of principal executive offices) (Zip Code)
(949) 284-4555 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of ClassTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.00001 per shareEOLSThe Nasdaq Stock Market LLC (Nasdaq Global Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On March 3, 2026, Evolus, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Eclipse Business Capital LLC, as administrative agent (the “Agent”) and the lenders party thereto.
The Loan Agreement provides for a senior secured asset-based revolving credit facility of up to $30.0 million (the “Revolving Credit Facility”), subject to a borrowing base formula based on eligible accounts receivable and eligible inventory, in each case reduced by customary reserves. The Revolving Credit Facility includes an uncommitted accordion feature of up to $10.0 million, exercisable subject to lender consent and other conditions. The Revolving Credit Facility is subject to a minimum utilization requirement of $10.0 million and matures on March 3, 2029.
Borrowings under the Revolving Credit Facility bear interest at a rate equal to adjusted term secured overnight financing rate (“SOFR”) (subject to a floor of 2.0%) plus an applicable margin of 4.25%, which is subject to downward adjustments based on certain coverage ratio and excess availability. The Revolving Facility and the Accordion Facility are subject to a closing fee equal to 1.0% and prepayment fees equal to 3.0% during the first year, 2.0% during the second year, and zero percent thereafter, subject to certain exceptions.
All obligations of the Company under the Loan Agreement are secured by substantially all of the assets of the Company, subject to customary exceptions.
The Loan Agreement requires the Company to maintain minimum excess availability at all times and limits capital expenditures. The Loan Agreement contains customary representations and warranties, affirmative and negative covenants and events of default, including cross-defaults to other material indebtedness, bankruptcy and insolvency-related events and a change of control. Upon the occurrence and continuation of an event of default, the Agent may terminate the commitments, accelerate all outstanding obligations and exercise remedies with respect to the collateral.
The foregoing description of the Loan Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 2.02 Results of Operations and Financial Condition.
On March 3, 2026, the Company issued a press release announcing its financial results for the quarter and year ended December 31, 2025. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan
Jan 9, 2026 · 100% conf.
1D
-7.03%
$5.27
5D
-10.69%
$5.06
20D
-8.67%
$5.17
eols-202601090001570562false00015705622026-01-092026-01-09
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2026
(Exact name of registrant as specified in its charter)
Delaware 001-38381 46-1385614
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
520 Newport Center Drive, Suite 1200 Newport Beach, California 92660 (Address of principal executive offices) (Zip Code)
(949) 284-4555 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of ClassTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.00001 per shareEOLSThe Nasdaq Stock Market LLC (Nasdaq Global Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 9, 2026, Evolus, Inc. (the "Company") issued a press release announcing its preliminary, unaudited net revenue and certain other operational and financial data for the quarter and year ended December 31, 2025. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1Press Release of Evolus, Inc., dated January 9, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Evolus, Inc.
Dated: January 9, 2026/s/ David Moatazedi
David Moatazedi
President and Chief Executive Officer
Nov 5, 2025
eols-202511050001570562false00015705622025-11-052025-11-05
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-38381 46-1385614
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
520 Newport Center Drive, Suite 1200 Newport Beach, California 92660 (Address of principal executive offices) (Zip Code)
(949) 284-4555 (Registrant’s telephone number, including area code)
N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of ClassTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.00001 per shareEOLSThe Nasdaq Stock Market LLC (Nasdaq Global Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2025, Evolus, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2025. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1Press Release of Evolus, Inc., dated November 5, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Evolus, Inc.
Dated: November 5, 2025 /s/ David Moatazedi
David Moatazedi
President and Chief Executive Officer
See how EOLS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "EOLS Evolus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.